Regeneron Pharmaceuticals logged a 5.4% change during today's evening session, and is now trading at a price of $771.45 per share. The S&P 500 index moved -0.0%. REGN's trading volume is 1,068,769 compared to the stock's average volume of 638,883.
Regeneron Pharmaceuticals trades -10.45% away from its average analyst target price of $861.52 per share. The 21 analysts following the stock have set target prices ranging from $650.0 to $1045.0, and on average have given Regeneron Pharmaceuticals a rating of buy.
Anyone interested in buying REGN should be aware of the facts below:
-
Regeneron Pharmaceuticals's current price is 75.4% above its Graham number of $439.76, which implies that at its current valuation it does not offer a margin of safety
-
Regeneron Pharmaceuticals has moved 25.0% over the last year, and the S&P 500 logged a change of 10.0%
-
Based on its trailing earnings per share of 36.84, Regeneron Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of 20.9 while the S&P 500 average is 15.97
-
REGN has a forward P/E ratio of 18.4 based on its forward 12 month price to earnings (EPS) of $41.87 per share
-
The company has a price to earnings growth (PEG) ratio of 6.48 — a number near or below 1 signifying that Regeneron Pharmaceuticals is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 3.52 compared to its sector average of 4.16
-
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
-
Based in Tarrytown, the company has 12,099 full time employees and a market cap of $84.64 Billion.